Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment

K. Pilatova, B. Bencsikova, R. Demlova, D. Valik, L. Zdrazilova-Dubska,

. 2018 ; 67 (12) : 1919-1929. [pub] 20180510

Language English Country Germany

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc19000747

Grant support
NV16-31966A MZ0 CEP Register

Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19000747
003      
CZ-PrNML
005      
20190115100914.0
007      
ta
008      
190107s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00262-018-2166-4 $2 doi
035    __
$a (PubMed)29748897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Pilatova, Katerina $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic.
245    10
$a Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment / $c K. Pilatova, B. Bencsikova, R. Demlova, D. Valik, L. Zdrazilova-Dubska,
520    9_
$a Myeloid-derived suppressor cells (MDSCs) have been shown to contribute to tumor escape from host immune surveillance and to cancer progression by production of tumor-promoting soluble factors. Granulocyte colony-stimulating factor (G-CSF) is a principle cytokine controlling granulocyte number. Recombinant human G-CSF (rhG-CSF) has become the main therapeutic agent for the treatment of neutropenia and prophylaxis of febrile neutropenia in cancer patients. However, we show here that rhG-CSF triggers accumulation of granulocytic and monocytic subsets. Consequently, we discuss the pharmacological use of granulopoiesis stimulating factors not only in the context of febrile neutropenia but also from the perspective of MDSC-dependent and MDSC-independent mechanisms of immunosuppression and cancer angiogenesis.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a nádorová transformace buněk $x genetika $x imunologie $x metabolismus $7 D002471
650    _2
$a faktor stimulující kolonie granulocytů $x metabolismus $x terapeutické užití $7 D016179
650    _2
$a lidé $7 D006801
650    _2
$a imunologická tolerance $7 D007108
650    _2
$a myeloidní supresorové buňky $x imunologie $x metabolismus $x patologie $7 D000072737
650    _2
$a nádory $x farmakoterapie $x imunologie $x metabolismus $7 D009369
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bencsikova, Beatrix $u RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Demlova, Regina $u RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic. Clinical Trial Unit, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Valik, Dalibor $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic.
700    1_
$a Zdrazilova-Dubska, Lenka $u Department of Laboratory Medicine, Masaryk Memorial Cancer Institute, Zluty kopec 7, 656 53, Brno, Czech Republic. dubska@mou.cz. RECAMO, Masaryk Memorial Cancer Institute, Brno, Czech Republic. dubska@mou.cz. Department of Pharmacology, Medical Faculty, Masaryk University, Brno, Czech Republic. dubska@mou.cz.
773    0_
$w MED00001041 $t Cancer immunology, immunotherapy CII $x 1432-0851 $g Roč. 67, č. 12 (2018), s. 1919-1929
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29748897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190115101124 $b ABA008
999    __
$a ok $b bmc $g 1364761 $s 1038870
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 67 $c 12 $d 1919-1929 $e 20180510 $i 1432-0851 $m Cancer immunology and immunotherapy $n Cancer Immunol Immunother $x MED00001041
GRA    __
$a NV16-31966A $p MZ0
LZP    __
$a Pubmed-20190107

Find record

Citation metrics

Archiving options